NetworkNewsBreaks Archive - Page 152 of 2091

ThursdayMay 01, 2025 12:51 pm

NetworkNewsBreaks – LaFleur Minerals Inc. (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0) Initiates Bulk Sample Permitting at Swanson Gold Project Ahead of Beacon Mill Restart

LaFleur Minerals (CSE: LFLR) (OTCQB: LFLRF) (FSE: 3WK0), has begun the permitting process to extract a 100,000-tonne surface bulk sample from its Swanson Gold Deposit in Quebec’s Abitibi Gold Belt. The mineralized material will be processed at LaFleur’s 100%-owned, fully permitted Beacon Gold Mill, located 50 km away. If deemed viable, the results will support a scoping study evaluating future production. The company aims to generate near-term cash flow while advancing exploration, with mill restart and gold production targeted by year-end 2025. Swanson currently hosts an indicated resource of 123,400 oz Au and inferred resource of 64,500 oz Au. To…

ThursdayMay 01, 2025 12:00 pm

NetworkNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Appoints Industry Veteran Jon Bond to Board of Directors

Onar (OTCQB: ONAR) announced the appointment of marketing pioneer Jon Bond to its board of directors. Bond, co-founder of Kirshenbaum & Bond and former CEO of Big Fuel, brings decades of experience in creative, digital, and programmatic media, having held leadership roles at top firms including Publicis and Inuvo (NYSE: INUV). His addition is expected to enhance ONAR’s M&A strategy, agency network growth, and brand credibility, reinforcing the company’s mission to redefine modern marketing through innovation and strategic expansion. To view the full article, visit https://nnw.fm/iWK7r About ONAR ONAR (OTCQB: ONAR) is a leading marketing technology company and marketing agency…

ThursdayMay 01, 2025 11:28 am

NetworkNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138

TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation. To view the full press release, visit https://nnw.fm/YLsH1 About TransCode Therapeutics TransCode is a clinical-stage oncology company…

ThursdayMay 01, 2025 10:51 am

NetworkNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Appoints Mining Executive Peter Espig to Board as Montauban Project Nears Production

ESGold (CSE: ESAU) (OTCQB: ESAUF) has appointed veteran mining executive and former global investment banker Peter Espig to its board of directors, as the company advances its fully permitted Montauban Gold-Silver Project in Quebec toward 2025 production. Espig brings decades of leadership across capital markets and mining operations, including a turnaround success as CEO of Nicola Mining. His appointment comes as ESGold focuses on production readiness, economic reassessment, 3D geological modeling and expanded exploration at Montauban. To view the full press release, visit https://nnw.fm/V2MbQ About ESGold Corp. ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) (FSE: Z7D) is a fully permitted, pre-production resource company…

ThursdayMay 01, 2025 10:24 am

NetworkNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Granted FDA Waiver for $4.3 Million NDA Filing Fee for NRX-100

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a $4.3 million New Drug Application filing fee waiver from the FDA for NRX-100, its preservative-free ketamine therapy for suicidal depression. The waiver, granted to small businesses and drugs deemed essential for public health, enables NRx to complete its NDA by the end of Q2 2025 using existing resources. NRX-100 offers a single-patient ketamine formulation without benzethonium chloride, a preservative associated with neurotoxicity. The company aims to secure FDA approval to provide insurance-covered treatment options beyond current off-label use. To view the full press release, visit https://nnw.fm/9OQDW About NRx Pharmaceuticals, Inc. NRx…

ThursdayMay 01, 2025 10:07 am

NetworkNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) to Host Webinar on PC111 Antibody for Rare Skin Disorders

Scinai Immunotherapeutics (NASDAQ: SCNI) will host a webinar May 7 at 11:30 a.m. EST to discuss the treatment potential of Pincell’s novel monoclonal antibody, PC111, for rare skin conditions Pemphigus Vulgaris and SJS/TEN. The session will cover unmet medical needs, PC111’s mechanism targeting soluble Fas ligand, and development plans. The event follows Scinai’s March agreement to acquire Pincell and a related €12 million grant application under Poland’s FENG program. Panelists include executives from Scinai and Pincell, with a live Q&A segment. To view the full press release, visit https://nnw.fm/E19h6 About Scinai Immunotherapeutics Ltd. Scinai is a biopharmaceutical company with two…

ThursdayMay 01, 2025 9:50 am

NetworkNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Appoints New CEO and President to Lead AI-Driven Hospitality Expansion

Nightfood Holdings (OTCQB: NGTF) has named Jimmy Chan as Chief Executive Officer and Ried Floco as President and Director, marking a major leadership transition aimed at accelerating the company’s growth in AI-powered hospitality automation and hotel operations. Chan brings capital markets and supply chain expertise, while Floco adds decades of hospitality leadership, including oversight of over 200 hotel properties. The appointments follow recent acquisitions of Skytech Automated Solutions and CarryOutSupplies.com, positioning Nightfood for vertically integrated expansion in the tech-enabled hospitality space. To view the full press release, visit https://nnw.fm/ptc86 About Nightfood Holdings Inc. Nightfood is a forward-thinking holding company dedicated to…

ThursdayMay 01, 2025 9:40 am

NetworkNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13

HeartBeam (NASDAQ: BEAT) will host a conference call on May 13 at 4:30 p.m. Eastern to discuss financial results for the first quarter ended March 31, 2025. CEO Robert Eno and CFO Timothy Cruickshank will lead the call, which will include updates on regulatory progress, commercial-readiness efforts, and upcoming milestones. A corresponding press release and presentation will be available on the company’s investor relations website. To view the full press release, visit https://nnw.fm/wAnm2 About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the…

ThursdayMay 01, 2025 9:20 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Aligns with Sustainable Football Investment Trends Highlighted by WSJ

Brera Holdings (NASDAQ: BREA) reaffirmed its commitment to a sustainable, community-focused multi-club ownership model, drawing parallels to trends highlighted in a recent Wall Street Journal article on the rise of U.S.-led football investments. The Company emphasized its strategic acquisition of Juve Stabia, now contending for Serie A promotion, as a prime example of its ladder-climbing approach. As the first publicly traded MCO group, Brera promotes long-term value creation by integrating local engagement, operational discipline, and public market transparency across its expanding global portfolio. To view the full press release, visit https://nnw.fm/V7VOt About Brera Holdings PLC Brera Holdings PLC is focused on…

ThursdayMay 01, 2025 9:10 am

NetworkNewsBreaks – First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) Successfully Road-Tests Thermoelectric Generator Radiator

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) announced that its majority-owned subsidiary, PyroDelta Energy, has completed over 800 miles of successful road testing for its thermoelectric generator/radiator, which uses tellurium to convert waste heat into electricity. The device, which replaces both the alternator and radiator in combustion engine vehicles, features no moving parts, improves fuel efficiency, and can be installed without modifying vehicle designs. CEO Tyrone Docherty said the results exceeded expectations, and Head Engineer Michael Abdelmaseh highlighted its adaptability for both new and existing vehicles. The company also noted potential applications in data centers and EVs. A shareholder luncheon will be…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks